Trial
NCT01972516
Tivozanib As Maintenance Therapy In GYN
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
National Comprehensive Cancer Network; AVEO Pharmaceuticals, Inc.
Condition
Ovarian Cancer
Intervention
Tivozanib
Why stopped
due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-05